louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01031992: Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Official title: Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hereditary Hemorrhagic Telangiectasia
Keywords: Hereditary hemorrhagic telangiectasia
Rendu-Osler-Weber syndrome
Epistaxis
Nosebleeds
Anemia
Tranexamic acid
Antifibrinolytics
Lead sponsor: University Hospital, Saarland
Sponsor class: OTHER
Collaborators: name: Pharmacia GmbH, Erlangen, Germany
name: Baxter Healthcare Corporation
First posted: 2009-12-15
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with frequent nosebleeds in the majority of cases. Several reports in the literature support the use of antifibrinolytics like Tranexamic acid to reduce nosebleeds. The objectives of the study are to test if Tranexamic acid taken orally can

1. improve anemia (lead to an increased hemoglobin level)
2. reduce nosebleeds.


Eligibility criteria: Inclusion Criteria:

* hereditary hemorrhagic telangiectasia with nosebleeds and desire to be treated.

Exclusion Criteria:

* pregnant,
* minor,
* had an increased risk of thrombotic events (history or signs of cerebrovascular events, cardiac arrhythmias, biochemically increased coagulation parameters),
* renal insufficiency,
* a history of massive hematuria or defects of color vision.

Primary outcomes:
measure: Change of hemoglobin level within the phases.
timeFrame: Beginning and end of each 3 months period.
Secondary outcomes:
measure: Mean epistaxis score (daily duration multiplied by mean subjective daily intensity)
timeFrame: Measured once a day during each 3 months period
Other outcomes:
Locations:
city: Homburg
country: Germany
facility: Universitätskliniken des Saarlandes, HNO-Abteilung
state: Saar
Study officials:
affiliation: Medical Faculty of the University of the Saarland and Hospitals of the City of Cologne
name: Urban W Geisthoff, Priv.-Doz. Dr.med.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Geisthoff UW, Seyfert UT, Kubler M, Bieg B, Plinkert PK, Konig J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014 Sep;134(3):565-71. doi: 10.1016/j.thromres.2014.06.012. Epub 2014 Jun 16.
Clinical trial NCT06997692: Effect of Gongs Mobilization With Neuromuscular Electrical Stimulation vs Conservative Exercises Among AC
Official title: Effect of Gongs Mobilization With Neuromuscular Electrical Stimulation vs Conservative Exercises Among Adhesive Capsulitis
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Adhesive Capsulitis
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2025-05-30
Enrollment: 36
Sex: ALL
Minimum age (years): 41
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study evaluates the effectiveness of Gong's mobilization combined with neuromuscular electrical stimulation versus conservative exercises in improving range of motion, pain relief, and functional outcomes in patients with adhesive capsulitis.

Detailed description: Using a randomized controlled design with 36 participants with estimated drop out 10% will be 40, the study will measure changes in active and passive shoulder mobility and SPADI scores after 6 weeks.

Eligibility criteria: Inclusion Criteria:

* Diagnosed cases of frozen shoulder confirmed by an orthopedician.
* Patients in stage II or III of adhesive capsulitis.
* Participants of both genders aged 41-60 years.
* Subjects with a restricted range of motion (ROM), with losses of 25% or greater compared to the unaffected shoulder.

Exclusion Criteria:

* Rotator cuff tears.
* Overuse injuries.
* History of rheumatoid arthritis, osteoarthritis, or malignancies in the shoulder region.
* Adhesive capsulitis secondary to neurological disorders.
* Unstable shoulders or recurrent dislocations.
* Post-surgical cases involving the shoulder.

Primary outcomes:
measure: Visual Analog Scale (VAS
timeFrame: 12 Months
measure: Shoulder Pain and Disability Index (SPADI)
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Gosha shifa hospital lahore gulshan ravi A block
state: Punjab
Study officials:
References:
Clinical trial NCT01369992: Molecular Profiling of Metastatic Cancer in Pleural Effusion and Ascites
Official title: Molecular Profiling of Metastatic Cancer in Pleural Effusion and Ascites
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Metastatic Cancer
Keywords: Metastatic Cancer
Lead sponsor: Taipei Medical University WanFang Hospital
Sponsor class: OTHER
First posted: 2011-06-09
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cancer patients

Brief summary: Cancers are among the most frequent leading causes of death in Taiwan, and many of them show their respective unique epidemiological and pathophysiological features in Taiwanese population. One of the distinguishing features of cancers includes their potential to metastasize outside the primary tumor. Pleural cavity and peritoneum are two of the most frequent sites of metastases when serosal surfaces are involved. The prognoses of such patients are extremely poor with a median survival of months. The understandings of cancer biology of tumor metastasis demand more in-depth studies at the molecular and cell levels. Studies based on cell culture are excellent approaches for this purpose as the cell culture provides a relevant and renewable model for studying the pathological and molecular changes underlying human malignant tumors.

Detailed description: Due to their easy accessibility, pleural effusions and ascites are two important clinical sources of metastatic cancer cells, which upon isolation, permit comparative studies between the biology nature of primary tumor and metastatic ones. In this study, we will try to isolate cancer cells from human malignant effusions, said to be pleural effusions and/or ascites. We will establish phenotypic alterations along the progression of malignant tumors with serosal metastasis, with special emphasis on expression of some proteases, laminin receptors and transcription factors involved in the process of invasion and metastasis. We would also perform clinical correlations, including tumor type, staging, status of lymph node metastasis and histopathological differentiation and grading, etc.

Eligibility criteria: Inclusion Criteria:

* cancer patients
* pleural effusion or peritoneal effusion

Exclusion Criteria:

* infected and fever patients
* anticoagulant treatment patients
* patients don't attend this study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University - WanFang Hospital
Study officials:
affiliation: Taipei Medical University WanFang Hospital
name: Tze-Sian Chan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00005492: Pooled Analysis of NHANES I/II--Race, Gender, and CHD
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Diseases
Coronary Disease
Heart Diseases
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Sponsor class: NIH
First posted: 2000-05-26
Sex: MALE
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: To conduct a pooled analysis of NHANES I/II data on race, gender, and coronary heart disease.

Detailed description: BACKGROUND:

Over the last 25 years, a sustained and marked decline in death rates from coronary heart disease (CHD) has occurred for all major segments of the U.S. population. Recently, however, the decline has proceeded less rapidly in blacks than in whites, and in women than men. These trends have focused further attention on possible heterogeneity in the risk factor patterns among the demographic sub-groups. Previous studies of CHD risk factors in blacks and whites using the First National Health and Examination Survey Epidemiologic Follow-up Study (NHEFS-I, 11-year follow-up), including this group's own work, demonstrate its potential strengths, while at the same time foundering on the problem of low statistical power. With the extension of the follow-up of NHANES-I cohort (1971-1974) to 1987 (14 years) and the completion of 14-year follow-up for NHANES II cohort (1976-1980), a strong rationale exists to undertake a "pooling project." The resulting data set would provide optimal characterization of CHD risk at the national level.

DESIGN NARRATIVE:

The study sought to determine whether data from NHANES I and NHANES II could be pooled. To accomplish this, the distribution of baseline measures was assessed and a determination was made whether the same logistic prediction equations fitted both studies. Also, gender-race differences were examined in individual exposure-outcome relationships, patterns of co-morbidity, and population attributable risks.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Eligibility criteria: No eligibility criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Loyola University
name: Youlian Liao
References:
citation: Liao Y, McGee DL, Cooper RS, Sutkowski MB. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J. 1999 May;137(5):837-45. doi: 10.1016/s0002-8703(99)70407-2.
Clinical trial NCT02311192: Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography
Official title: Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Uveitis
Keywords: Vitreous Haze
Ocular ultrasound
B scan
Uveitis
Lead sponsor: University of Nebraska
Sponsor class: OTHER
Collaborators: name: Post Graduate Institute of Medical Education and Research, Chandigarh
name: Luigi Sacco University Hospital
First posted: 2014-12-08
Enrollment: 0
Sex: ALL
Minimum age (years): 19
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is aimed at creation and validation of a vitreous haze scoring system using ultrasonography B-scan of the eye. Images will be obtained from patients with uveitis and quantification of inflammation will be done to create the scoring scale.

Detailed description: Patients with uveitis may present with Vitreous Haze (VH) resulting in obscuration of fundus details. VH is composed of cells and protein exudation and results in decrease visual acuity.The degree of VH is an important indicator of disease activity, severity and response to therapy in patients with uveitis. Color fundus images are commonly used to objectively document VH.

Eligibility criteria: Inclusion Criteria:

* • Ability to provide written informed consent and comply with study assessments for the full duration of the study

  * Age 18 -90 years
  * Diagnosis of uveitis

Exclusion Criteria:

* • Patients with posterior segment complications including retinal detachment, choroidal detachment or hemorrhage

  * Patients with any intraocular foreign body or displaced intraocular lens
  * Patients with silicon oil filled eye or with gas tamponade.
  * Patients with vitreous hemorrhage
  * Patients with media opacity including visually significant cataract that precludes grading of VH based on fundus photography

Primary outcomes:
measure: Inter-observer correlation for vitreous haze grading
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Nebraska
name: Quan D Nguyen, MD MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Luigi Sacco Hospital
name: Giovanni Staurenghi, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Post Graduate Institute of Medical Education and Research, Chandigarh
name: Ramandeep Singh, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05513092: Placenta Accreta Index Score in Placenta Accreta Spectrum
Official title: Role of Placenta Accreta Index in Predicting Conservative Surgery for Placenta Accreta Spectrum
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Placenta Accreta, Third Trimester
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2022-08-24
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: • Pregnant women above 28 weeks gestation by 1st trimesteric U/S,2nd trimesteric U/S or sure reliable dates; diagnosed as placenta previa by 2D ultrasound, Doppler on placental bed.

Patients who have done one or more cesarean sections

Brief summary: role of placenta accreta index score in prediction of conservative surgery for placenta placenta accreta spectrum

Detailed description: in this study ,we will recruit 60 cases diagnosed placenta previa accreta by 2D ultrasound and Doppler then patients will have 3D Doppler to calculate placenta accreta index score according to agarawl et al criteria , patients will have cs accroding to our hospital protocol "Al demerdash maternity hospital ,Ainshams university" .Intraoperative findings will be noticed ,postoperative histopathological examination may br needed in cases of cs hystrectomy ,placenta accreta index score will be compared to intra and postoperative findings , patients will be followed up for two weeks after delivery for any postoperative complication

Eligibility criteria: Inclusion Criteria:

* • Pregnant women above 28 weeks gestation by 1st trimesteric U/S,2nd trimesteric U/S or sure reliable dates; diagnosed as placenta previa by 2D ultrasound, Doppler on placental bed.

  * Patients who have done one or more cesarean sections

Exclusion Criteria:

* Patients who refuse to participate in our study.

Primary outcomes:
measure: Accuracy of PAS index score in prediction of conservative surgery
timeFrame: 2022 to 2024
Secondary outcomes:
measure: Intraoperative blood loss
timeFrame: at delivery
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ainshams university
Study officials:
affiliation: Ainshams university
name: Ahmed M Mamdouh
role: STUDY_DIRECTOR
References:
Clinical trial NCT03457389: Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
Official title: Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pituitary Adenoma
Prolactinoma
Pituitary Tumor
Recurrence Tumor
Keywords: Prolactinoma
Cabergoline
Recurrence
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2018-03-07
Enrollment: 68
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: One experimental group and one control group
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate whether inhibition of serum prolactin levels below normal range during cabergoline administration may reduce the recurrence rate after drug withdrawal in patients with prolactinomas.

Detailed description: Prolactinoma patients will be assigned to a experimental group that maintains serum prolactin levels below 5 ng/mL and a control group that maintains normal serum prolactin levels. After that, cabergoline will be maintained at a therapeutic dose for 130 weeks. After cabergoline is discontinued, patients will be followed up with serum prolactin measurement for 52 weeks.

Eligibility criteria: Inclusion Criteria:

* Adults, male or female aged 19 years or older
* diagnosed with prolactinoma
* No previous history of surgery, medication, or radiation therapy

Exclusion Criteria:

* Invasive prolactinomas except invading cavernous sinus
* Taking dopaminergic medications
* Taking medications that can affect serum prolactin level (including estrogenic hormone, oral contraceptive drugs, intrauterine devices)
* Hyperprolactinemia due to secondary causes
* History of pituitary apoplexy within the last 3 months
* Patients with mental illness that should avoid dopamine agonists
* Patients with history of cardiac valve diseases
* Patients with history of pulmonary fibrosis, retroperitoneal fibrosis, and cystic fibrosis
* Moderate degree of hepatic or renal insufficiency (IDMS Modification of Diet in Renal Disease glomerular filtration rate (MDRD GFR) \<45 ml/min/1.73m2)
* Patients with cabergoline hypersensitivity reaction
* Pregnant or breast feeding patients

Primary outcomes:
measure: Recurrence rate within 1 year after cabergoline withdrawal
timeFrame: From 4 year to 5 years after cabergoline administration
Secondary outcomes:
measure: Time to normalization of serum prolactin level
timeFrame: Up to 1 year
measure: Change from baseline on tumor volume measured by pituitary MRI
timeFrame: Up to 3 years
measure: Change from baseline of visual field defect
timeFrame: Up to 3 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jung Hee Kim, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01655589: VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents
Official title: VEGF Gene Polymorphism and Response to Intravitreal Anti-VEGF Agents in Neovascular Age-related Macular Degeneration
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Macular Degeneration
Lead sponsor: Institute of Vision, Brasil
Sponsor class: OTHER
First posted: 2012-08-02
Enrollment: 74
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Eye clinic in Belo Horizonte, Brazil

Brief summary: The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of neovascular age-related macular degeneration
* Visual acuity better than 20/400
* Loading dose with three intravitreal injections of anti-VEGF agents, administred one per month over three months
* Follow-up period of at least six months

Exclusion Criteria:

* Choroidal neovascularization secondary to any other cause than age-related macular degeneration
* Eyes with polypoidal choroidal vasculopathy
* Eyes previously submitted to posterior vitrectomy
* Other diseases that could affect visual acuity

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Belo Horizonte
country: Brazil
facility: Institute of Vision
state: MG
Study officials:
References:
Clinical trial NCT02314689: A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Sickle Cell Disease
Lead sponsor: University of Mississippi Medical Center
Sponsor class: OTHER
First posted: 2014-12-11
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the maximum tolerated dose, safety and pharmacokinetics of an investigational drug, intravenous (IV) citrulline, in subjects in steady-state sickle cell disease.


Eligibility criteria: Inclusion Criteria:

* Sickle cell disease genotypes (HbSS, HbS/β° thalassemia, HbS/β+thalassemia, HbSC)

Exclusion Criteria:

* Presence of any acute illness defined by fever \>100.4° F within the past 48 hours
* Presence of sickle cell pain crisis defined by the presence of pain requiring oral or parental opioid therapy.
* Presence of acute chest syndrome or presence of any other complication related to sickle cell disease requiring hospitalization such as splenic sequestration, hepatic sequestration, stroke, avascular necrosis of the hip/shoulder, acute priapism, and patients with diabetes etc.
* Severe anemia (hemoglobin \< 5g/dL)
* History of red blood cell transfusion within the last 14 days
* Systemic steroid therapy within the last 48 hours
* Pregnant (as confirmed by a negative urine pregnancy test) or lactating female
* Alanine/aspartate transferase \>2x upper limit of normal laboratory range for age.
* Elevated serum creatinine \>1.5mg/dL
* Patients with an inability to give consent will be excluded
* Medications that are known to be contra-indicated with use of L-citrulline (concurrent use of hydroxyurea will be allowed).
* History of diabetes due to risk of electrolyte imbalance

Primary outcomes:
measure: Number of Participants With Grade 2 or Higher Adverse Event According to NCI Criteria
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Jackson
country: United States
facility: University of Mississippi Medical Center
state: Mississippi
Study officials:
References:
citation: Barr FE, Tirona RG, Taylor MB, Rice G, Arnold J, Cunningham G, Smith HA, Campbell A, Canter JA, Christian KG, Drinkwater DC, Scholl F, Kavanaugh-McHugh A, Summar ML. Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg. 2007 Aug;134(2):319-26. doi: 10.1016/j.jtcvs.2007.02.043.